STUDYID | USUBJID | ASEQ | BSABASE | PARAM | PARAMCD | AVAL | AVISIT | AVISITN | VISIT | ADT | ABLFL | BASE | CHG | PCHG | CHGCAT1 | LBSTRNRLO | LBSTRNHI | LBNRIND | TRT01P | ITTFL | AGE | AGEU | SEX | SRCDOM | SRCSEQ | DMD-EFLGE | DMD-EFLGE-101 | 1 | 0.65 | Left Ventricular Ejection Fraction, Calculated (%) | LVEFC | 67 | Visit 1 (Month 1) | 1 | VISIT 1 | 16May2022 | Y | 67 | Treatment A | Y | 8 | YEARS | M | CV | 3 | DMD-EFLGE | DMD-EFLGE-101 | 2 | 0.65 | Right Ventricular Ejection Fraction, Calculated (%) | RVEFC | 74 | Visit 1 (Month 1) | 1 | VISIT 1 | 16May2022 | Y | 74 | Treatment A | Y | 8 | YEARS | M | CV | 7 | DMD-EFLGE | DMD-EFLGE-101 | 3 | 0.65 | N-Terminal ProB-type Natriuretic Peptide (IU/L) | BNPPRONT | 40 | Visit 1 (Baseline) | 1 | VISIT 1 | 16May2022 | Y | 40 | 100 | 40 | NORMAL | Treatment A | Y | 8 | YEARS | M | LB | 1 | DMD-EFLGE | DMD-EFLGE-101 | 4 | 0.65 | Left Ventricular Ejection Fraction, Calculated (%) | LVEFC | 60 | Visit 6 (Month 12) | 6 | VISIT 6 | 01Jun2023 | 67 | -7 | -10.447761 | Treatment A | Y | 8 | YEARS | M | CV | 11 | DMD-EFLGE | DMD-EFLGE-101 | 5 | 0.65 | Right Ventricular Ejection Fraction, Calculated (%) | RVEFC | 61 | Visit 6 (Month 12) | 6 | VISIT 6 | 01Jun2023 | 74 | -13 | -17.567568 | Treatment A | Y | 8 | YEARS | M | CV | 10 | DMD-EFLGE | DMD-EFLGE-101 | 6 | 0.65 | N-Terminal ProB-type Natriuretic Peptide (IU/L) | BNPPRONT | 900 | Visit 6 (1 Year) | 6 | VISIT 1 | 1Jun2023 | 40 | 860 | 2150 | 100 | 900 | HIGH | Treatment A | Y | 8 | YEARS | M | LB | 11.8 | Row | STUDYID | USUBJID | ASEQ | BSABASE | PARAM | PARAMCD | AVAL | AVISIT | AVISITN | VISIT | ADT | ABLFL | BASE | CHG | PCHG | CHGCAT1 | LBSTRNRLO | LBSTRNRHI | LBNRIND | TRT01P | ITTFL | AGE | AGEU | SEX | SRCDOM | SRCSEQ |
---|
1 | DMD-EFLGE | DMD-EFLGE-101 | 1 | 0.65 | Left Ventricular Ejection Fraction, Calculated (%) | LVEFC | 67 | Visit 1 (Month 1) | 1 | VISIT 1 | 16May2022 | Y | 67 |
|
|
|
|
|
| Treatment A | Y | 8 | YEARS | M | CV | 3 | 2 | DMD-EFLGE | DMD-EFLGE-101 | 2 | 0.65 | Right Ventricular Ejection Fraction, Calculated (%) | RVEFC | 74 | Visit 1 (Month 1) | 1 | VISIT 1 | 16May2022 | Y | 74 |
|
|
|
|
|
| Treatment A | Y | 8 | YEARS | M | CV | 7 | 3 | DMD-EFLGE | DMD-EFLGE-101 | 3 | 0.65 | N-Terminal ProB-type Natriuretic Peptide (IU/L) | BNPPRONT | 40 | Visit 1 (Baseline) | 1 | VISIT 1 | 16May2022 | Y | 40 |
|
|
| 100 | 40 | NORMAL | Treatment A | Y | 8 | YEARS | M | LB | 1 | 4 | DMD-EFLGE | DMD-EFLGE-101 | 4 | 0.65 | Left Ventricular Ejection Fraction, Calculated (%) | LVEFC | 60 | Visit 6 (Month 12) | 6 | VISIT 6 | 01Jun2023 |
| 67 | -7 | -10.447761 |
|
|
|
| Treatment A | Y | 8 | YEARS | M | CV | 11 | 5 | DMD-EFLGE | DMD-EFLGE-101 | 5 | 0.65 | Right Ventricular Ejection Fraction, Calculated (%) | RVEFC | 61 | Visit 6 (Month 12) | 6 | VISIT 6 | 01Jun2023 |
| 74 | -13 | -17.567568 |
|
|
|
| Treatment A | Y | 8 | YEARS | M | CV | 10 | 6 | DMD-EFLGE | DMD-EFLGE-101 | 6 | 0.65 | N-Terminal ProB-type Natriuretic Peptide (IU/L) | BNPPRONT | 900 | Visit 6 (1 Year) | 6 | VISIT 1 | 1Jun2023 |
| 40 | 860 | 2150 |
| 100 | 900 | HIGH | Treatment A | Y | 8 | YEARS | M | LB | 2 |
|